Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check16 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedThe page now displays a new revision label: Revision: v3.4.2. This is a minor meta-update and does not alter study details or eligibility information.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision: v3.4.1 added and v3.4.0 removed; this appears to be an internal version update with no changes to the page content or study information.SummaryDifference0.1%

- Check60 days agoChange DetectedA glossary toggle was added and QC/version metadata was updated (Last Update Submitted that Met QC Criteria and Revision: v3.4.0); FEAR Act data labeling was adjusted.SummaryDifference0.2%

- Check74 days agoChange DetectedRevision v3.3.4 was added and Revision v3.3.3 was removed; this is a routine page update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.